Dear Sir,

Myasthenic Crisis (MC) is a life-threatening presentation of Myasthenia Gravis (MG), and is precipitated by infection, aspiration, hot weather, stress, drugs, drug default and surgery \[[@bib1],[@bib2]\]. The 2019 novel coronavirus (COVID 19) pandemic and lockdown has resulted in fear of infection and non-availability of drugs in patients with chronic diseases. We report a patient with MG whose MC was triggered by anxiety and insomnia during the COVID 19 pandemic.

A 54-year-old male presented with dyspnoea, ptosis, bulbar weakness and quadriparesis for five days without a known trigger of MC. He has been a known case of MG for 16 years, and was hospitalised several times due to MC ([Table 1](#tbl1){ref-type="table"} ). He had thymectomy and was stable for two years with pyridostigmine, prednisolone and azathioprine. His single breath count was seven. Blood counts, serum chemistry, thyroid profile, electrocardiogram and chest radiograph were normal. He required non-invasive ventilation and prostigmine injection. On the 35th day of hospitalisation, he informed staff that he could not sleep "ever" since the corona epidemic began in India. His Hospital Anxiety and Depression Scale-A score was 12. He was counselled about COVID prevention, and prescribed alprazolam 0.125 mg at night followed by melatonin 3 mg. His sleep improved and paralleled with improvement in myasthenic weakness.Table 1Clinical and treatment details during hospitalizations over 16 year follow up.Table 1SR NoAdmissionPrecipitating factorMGFA ClassType of Respiratory supportPlasmapheresis/IVIGDuration of hospital stay(days)Medications at discharge(Drugs with total daily mg dose)1.May 2005Missed doseIIIbBIPAPIVIG14Pyridostigmine (240)Prostigmine (15)Pyridostigmine (180)Prednisolone (20)2.June 2005Thymectomy & left pneumothoraxIIIbBIPAP4 cycles of plasmapheresis39Pyridostigmine (240)Prostigmine (15)Pyridostigmine (180)Prednisolone (20)3.Nov 2007Lower respiratory tract infectionIIbOxygenIVIG10Pyridostigmine (300)Prostigmine (45)Azathioprine (50)Prednisolone (20)Ramipril (2.5 mg)Sulfamethoxazole trimethoprim (800 + 160)4.March 2008Cholinergic crisisIIbOxygenNone11Pyridostigmine (300)Prostigmine (15)Azathioprine (50)Prednisolone (15)Ramipril (2.5)5.April 2008Lower respiratory tract infectionIIIbBIPAPIVIG11Pyridostigmine (300)Prostigmine (15)Azathioprine (50)Prednisolone (15)Ramipril (2.5)6.Sep 2008Lower respiratory tract infectionIIIbBIPAPNone7Pyridostigmine (214)Prostigmine (15)Azathioprine (50)Prednisolone (10/5) alternate day7.Aug 2010Lower respiratory tract infectionVventilatorplasmapheresis21Pyridostigmine (300)Azathioprine (50)Prednisolone (10)8.Aug 2014Lower respiratory tract infectionIIIbBIPAPIVIG20Pyridostigmine (180)Prostigmine (30)Azathioprine (100)Prednisolone (10)9.Apr 2016Lower respiratory tract infectionVVentilatorIVIG32Pyridostigmine (180)Azathioprine (100)Prednisolone (20)10.June 2018Hot weather Low back painIIbOxygenNone30Pyridostigmine (180)Azathioprine (150)Prednisolone (5)Telmisartan (80)Metformin (500)11.Aug 2018FluoroquinoloneIIIbBIPAPIVIG30Pyridostigmine (240)Prostigmine (30)Azathioprine (150)Prednisolone (10)Telmisartan (40)Metformin (500)12.Sep 2018FluoroquinoloneIIIbBIPAPplasmapheresis20Pyridostigmine (240)Prostigmine (45)Azathioprine (150)Prednisolone (10)Telmisartan (40)Metformin (1000)

This patient highlights anxiety and insomnia as a trigger of MC. Emotional stress as a trigger of MC has been reported in one patient only who had concomitant Takotsubo myopathy \[[@bib3]\]. Beta agonist increases cAMP at the neuromuscular junction leading to augmentation of acetylcholine quantal release and stabilization of acetylcholine receptors, but these effects may be offset by receptor desensitization at higher concentrations \[[@bib4],[@bib5]\]. We have used small dose of alprazolam when he failed to respond to all the measures. Although sedation or anxiolytic is contraindicated in MC, these may be life-saving in appropriate settings. Therefore, attention to neuropsychiatric status is important in MG.
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